Biocure Technology Inc.
Biocure Technology Inc.
Indice CSE:
Devise:
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE)
SEDAR Information
Information d'entreprise
Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaTéléphone
604-609-7146Fax
N/ACourriel
admin@biocuretech.comURL
http://www.biocuretech.comDate d’inscription à la cote
Lundi, mai 10, 2010Relations avec les investisseurs
n/aVérificateur
DMCL Chartered Professional AccountantsCapitalisation
Capitalisation:
94000537Réservé à l'émission:
14510547Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
Communiqués de presse
Bulletins
18/09/2023
2023-0927 - Arrêté pour un Changement Fondamental - Biocure Technology Inc. (CURE)
le 18 septembre/September 2023
Trading in the shares of Biocure Technology Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Acquisition pursuant to CSE Policy 8. This regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange, pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.
